GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Payments to Suppliers for Goods and Services

Samsung BioLogics Co (XKRX:207940) Payments to Suppliers for Goods and Services


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Payments to Suppliers for Goods and Services?

Payments to Suppliers for Goods and Services only applicable to companies reporting Cash Flow from Operations in direct method.


Samsung BioLogics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Payments to Suppliers for Goods and Services
Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.